CASRN: 131986-45-3; 47608-32-2
SID: 388765364; 433990217
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of xanomeline or trospium during breastfeeding. Trospium is unlikely to enter milk because it is a charged molecule. If a mother requires xanomeline and trospium, it is not a reason to discontinue breastfeeding. Monitor the infant for vomiting, diarrhea, abnormal movements and adequate weight gain.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Xanomeline and Trospium
CAS Registry Number
131986-45-3; 47608-32-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Antipsychotic Agents
Parasympathomimetics
Psychotropic Drugs
Muscarinic Agonists
Parasympatholytics
Muscarinic Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: April 15, 2025.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Xanomeline and Trospium. [Updated 2025 Apr 15].